Diabetic neuropathies are the most common complication of diabetes. Neuropathies can result in the loss of muscle strength, muscle atrophy and slowed nerve and muscle regeneration. The mechanisms for nerve and muscle degeneration in diabetes are unknown, but there is increasing evidence that edificencies in neurothrophic factors are major contributors in the development of neuropathies. IGF-1 is a potent glucoregulator and neurotrophic factor in muscle that promotes glucose transport, muscle myogenesis and maintenance of muscle function and structure. Its decreased levels in diabetic skeletal muscle may contribute to the die-back of motor neurons that lead to muscle atrophy and loss of muscle strength. This proposal is based on the hypothesis that IGF-1 can aid in reversing the metabolic and myogenic deficits of diabetes and therefore can be used as a potential muscle- based gene therapy to prevent or treat diabetic neuropathies. This hypothesis will be tested using IGF-1 transgenic mice, which overexpress IGS in muscle, to examine the role of IGS-1 in diabetic neuropathies. Studies will (1) examine whether IGF-1 can enhance glucose transport, by measuring 3H-2-dexyglocose uptake and enhanced expression of glucose transporter proteins GLUT1 and GLUT4, (2) examine the role of muscle transcription factors in the pathogenesis of muscle neuropathies and (3) test the ability of muscle- expressed IGF-1 to enhance nerve regeneration in diabetic mice. Studies will then test novel IGF-1 DNA constructs, injected into muscle, to reverse nerve and muscle degeneration in diabetic mice. The importance of these studies are 2-fold: (1) to identify the in vivo mechanisms by which IGF-1 protects nerve and muscle from diabetic degeneration and (2) to test the potential use of locally expressed IGF- 1 as a gene therapy to prevent or treat diabetic neuropathies that affect muscle and nerves.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29NS035613-05
Application #
6393822
Study Section
Neurology B Subcommittee 2 (NEUB)
Program Officer
Porter, John D
Project Start
1997-05-01
Project End
2005-04-30
Budget Start
2001-05-01
Budget End
2005-04-30
Support Year
5
Fiscal Year
2001
Total Cost
$103,600
Indirect Cost
Name
Baylor College of Medicine
Department
Surgery
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Rabinovsky, Eric D (2004) The multifunctional role of IGF-1 in peripheral nerve regeneration. Neurol Res 26:204-10
Rabinovsky, Eric D; Draghia-Akli, Ruxandra (2004) Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis. Mol Ther 9:46-55